Sheila Raghavan, Dina Abbas, Beverly Winikoff
Gynuity Health Projects, New York, NY 10010, USA. dabbas@gynuity.org
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2012 OctMisoprostol is an effective and safe uterotonic for the prevention and treatment of postpartum hemorrhage (PPH). A 600-μg oral dose of misoprostol has been shown to prevent PPH in community-based randomized controlled trials. An 800-μg sublingual dose of misoprostol appears to be a good first-line treatment for controlling PPH. Adverse effects after use of misoprostol for PPH prevention or treatment may include shivering and fever. These effects are transient, resolve on their own, and are not life threatening. Misoprostol can play an important role in settings with limited access to oxytocin, and where there is no other option for PPH care. Copyright © 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
Sheila Raghavan, Dina Abbas, Beverly Winikoff. Misoprostol for prevention and treatment of postpartum hemorrhage: what do we know? What is next? International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2012 Oct;119 Suppl 1:S35-8
PMID: 22883912
View Full Text